Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Itraconazole
Drug ID BADD_D01217
Description One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
Indications and Usage For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
Marketing Status Prescription; Discontinued
ATC Code J02AC02
DrugBank ID DB01167
KEGG ID D00350
MeSH ID D017964
PubChem ID 55283
TTD Drug ID D0V4IB
NDC Product Code 12578-299; 50268-450; 53069-0450; 58032-0110; 0378-5100; 68382-697; 66577-044; 63629-8168; 60687-299; 10147-0150; 70518-3264; 50458-290; 62991-3078; 10147-1700; 71747-002; 65162-630; 67835-5043; 16729-271; 10695-064; 22568-1108; 67877-454; 31722-006; 65162-087; 46708-204; 38779-2759; 62332-204; 60592-318; 72761-019; 70771-1208; 49884-239; 70518-2872; 66039-815; 17511-114; 50458-295; 59349-0012; 13668-463; 0395-8113; 71052-301; 50546-462; 16714-743; 51552-0920; 65015-624; 51862-462
Synonyms Itraconazole | R-51211 | R 51211 | R51211 | Sporanox | Orungal
Chemical Information
Molecular Formula C35H38Cl2N8O4
CAS Registry Number 84625-61-6
SMILES CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C 7=C(C=C(C=C7)Cl)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoaldosteronism05.01.02.009; 14.11.01.0310.009282%Not Available
Hypocalcaemia14.04.01.004--
Hypokalaemia14.05.03.0020.092824%
Hypomagnesaemia14.04.02.001--
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.002--
Ileus07.13.01.0010.009282%
Ileus paralytic07.02.05.0010.018565%Not Available
Immune system disorder10.02.01.001--Not Available
Implant site reaction12.07.02.009; 08.02.02.009--Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Infection11.01.08.002--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.0330.013924%Not Available
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.0300.074259%Not Available
Joint swelling15.01.02.0040.013924%Not Available
Laryngeal pain22.02.05.036--
Left ventricular failure02.05.02.001--Not Available
Lethargy19.04.04.004; 08.01.01.008; 17.02.04.0030.013924%
Leukopenia01.02.02.0010.009282%Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Liver abscess11.01.18.001; 09.01.11.0010.009282%Not Available
Liver disorder09.01.08.0010.032488%Not Available
Liver function test abnormal13.03.01.0130.051053%Not Available
Loss of consciousness17.02.04.004--Not Available
Lung disorder22.02.07.0010.002421%Not Available
Lung infiltration22.01.02.004--Not Available
Lymphadenopathy01.09.01.0020.013924%Not Available
Lymphopenia01.02.02.0020.009282%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 12 Pages